title: Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
abstract: Cryptococcus gattii is responsible for an expanding epidemic of serious infections in Western Canada and the Northwestern United States (Pacific Northwest). Some patients with these infections respond poorly to azole antifungals, and high azole MICs have been reported in Pacific Northwest C. gattii. In this study, multiple azoles (but not amphotericin B) had higher MICs for 25 Pacific Northwest C. gattii than for 34 non-Pacific Northwest C. gattii or 20 Cryptococcus neoformans strains. We therefore examined the roles in azole resistance of overexpression of or mutations in the gene (ERG11) encoding the azole target enzyme. ERG11/ACT1 mRNA ratios were higher in C. gattii than in C. neoformans, but these ratios did not differ in Pacific Northwest and non-Pacific Northwest C. gattii strains, nor did they correlate with fluconazole MICs within any group. Three Pacific Northwest C. gattii strains with low azole MICs and 2 with high azole MICs had deduced Erg11p sequences that differed at one or more positions from that of the fully sequenced Pacific Northwest C. gattii strain R265. However, the azole MICs for conditional Saccharomyces cerevisiae erg11 mutants expressing the 5 variant ERG11s were within 2-fold of the azole MICs for S. cerevisiae expressing the ERG11 gene from C. gattii R265, non-Pacific Northwest C. gattii strain WM276, or C. neoformans strains H99 or JEC21. We conclude that neither ERG11 overexpression nor variations in ERG11 coding sequences was responsible for the high azole MICs observed for the Pacific Northwest C. gattii strains we studied.
authors: Infectious Diseases Division, Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.
authors: Charles E
authors: CE
authors: Gast
authors: Luiz R
authors: LR
authors: Basso
authors: Igor
authors: I
authors: Bruzual
authors: Brian
authors: B
authors: Wong
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D002170:Canada / Q000453:epidemiology; D003453:Cryptococcosis / Q000453:epidemiology / Q000382:microbiology; D056285:Cryptococcus gattii / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D025141:Drug Resistance, Fungal / Q000235:genetics*; D015725:Fluconazole / Q000494:pharmacology; D005656:Fungal Proteins / Q000235:genetics* / Q000378:metabolism; D015870:Gene Expression; D005816:Genetic Complementation Test; D006801:Humans; D008826:Microbial Sensitivity Tests; D009154:Mutation; D015205:Northwestern United States / Q000453:epidemiology; D012441:Saccharomyces cerevisiae / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D058886:Sterol 14-Demethylase / Q000235:genetics* / Q000378:metabolism
chemical_list: D000935:Antifungal Agents; D005656:Fungal Proteins; D000666:Amphotericin B; D015725:Fluconazole; D058886:Sterol 14-Demethylase
references: Med Mycol. 2011 Apr;49(3):276-84
references: 20831364
references: Clin Infect Dis. 1995 Jul;21(1):28-34; discussion 35-6
references: 7578756
references: J Med Microbiol. 2004 Sep;53(Pt 9):935-940
references: 15314203
references: MMWR Morb Mortal Wkly Rep. 2010 Jul 23;59(28):865-8
references: 20651641
references: Antimicrob Agents Chemother. 1996 Dec;40(12):2835-41
references: 9124851
references: Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents
references: 19366916
references: Med Mycol. 2001 Apr;39(2):155-68
references: 11346263
references: J Antimicrob Chemother. 2008 Jul;62(1):205-6
references: 18375969
references: Emerg Infect Dis. 2010 Feb;16(2):251-7
references: 20113555
references: Microbiology (Reading). 2009 May;155(Pt 5):1547-1557
references: 19383674
references: Clin Microbiol Infect. 2008 Jul;14(7):727-30
references: 18558948
references: Clin Infect Dis. 1995 Mar;20(3):611-6
references: 7756484
references: Infect Immun. 2006 Feb;74(2):1352-9
references: 16428784
references: J Clin Microbiol. 2007 Sep;45(9):3086-8
references: 17596366
references: Diagn Microbiol Infect Dis. 2012 Jun;73(2):144-8
references: 22494557
references: Eukaryot Cell. 2010 Jun;9(6):960-70
references: 20348384
references: Biochim Biophys Acta. 2002 Jul 18;1587(2-3):240-8
references: 12084466
references: Emerg Infect Dis. 2009 Aug;15(8):1185-91
references: 19757550
references: J Infect Dis. 2009 Apr 1;199(7):1081-6
references: 19220140
references: Clin Infect Dis. 2012 Sep;55(6):789-98
references: 22670042
references: Antimicrob Agents Chemother. 1997 Jul;41(7):1488-94
references: 9210671
references: J Clin Microbiol. 2010 Feb;48(2):539-44
references: 20007380
references: Genetics. 1989 May;122(1):19-27
references: 2659436
references: Clin Infect Dis. 2011 Dec;53(12):1188-95
references: 22016503
references: PLoS Pathog. 2010 Apr 01;6(4):e1000848
references: 20368972
references: Antimicrob Agents Chemother. 2012 Mar;56(3):1162-9
references: 22155829
references: Biochem Biophys Res Commun. 2004 Nov 12;324(2):719-28
references: 15474487
references: Antimicrob Agents Chemother. 1998 Feb;42(2):241-53
references: 9527767
references: Antimicrob Agents Chemother. 2003 Nov;47(11):3653-6
references: 14576140
references: Rev Iberoam Micol. 2008 Mar;25(1):S4-12
references: 18338917
references: Antimicrob Agents Chemother. 1998 Dec;42(12):3065-72
references: 9835492